Skip to content
ClinCalc Pro
Menu
Progestogen-only contraceptive (POP)

Desogestrel

Brand names: Cerazette, Cerelle

Desogestrel is a progestogen used as a progestogen-only oral contraceptive ('mini-pill').

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It acts primarily by inhibiting ovulation, supplemented by thickening of cervical mucus to impede sperm penetration and changes to the endometrium.

Prescribing in practice

  • Unlike traditional progestogen-only pills, desogestrel reliably suppresses ovulation, but a missed pill beyond the permitted window still requires additional contraceptive precautions and consideration of emergency contraception.
  • It can be used in many women in whom oestrogen is contraindicated, including during breastfeeding.
  • Irregular or unpredictable bleeding is the most common reason for discontinuation and should be discussed before starting.

Monitoring

No specific laboratory monitoring is required; assess blood pressure and review contraceptive needs and any new bleeding pattern at follow-up.

Counselling the patient

  • Take one tablet at the same time each day without a break between packs.
  • If a pill is taken late beyond the allowed window, use additional precautions such as condoms as advised.
  • Irregular bleeding or spotting is common, especially in the early months.

Evidence & guidelines

Desogestrel-only contraception is recommended within UK guidance as an effective oestrogen-free option, including for breastfeeding women.

Reference: FSRH POP guideline; UKMEC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.